Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.

ABSTRACT:

Aims

Chemotherapy-induced peripheral neuropathy (PN) is a treatment limiting toxicity of paclitaxel. We evaluated if EPHA genetic variation (EPHA4, EPHA5, EPHA6, and EPHA8) is associated with PN sensitivity by accounting for variability in systemic paclitaxel exposure (time above threshold).

Methods

Germline DNA from 60 patients with breast cancer was sequenced. PN was measured using the 8-item sensory subscale (CIPN8) of the patient-reported CIPN20. Associations for 3 genetic models were tested by incorporating genetics into previously published PN prediction models integrating measured paclitaxel exposure and cumulative treatment. Significant associations were then tested for association with PN-related treatment disruption.

Results

EPHA5 rs7349683 (minor allele fre

SUBMITTER: Marcath LA 

PROVIDER: S-EPMC7163383 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature